Greene Concepts Inc (INKW): Lenny has sold his soul several times to...

tyhub · 2021-05-04T20:02:15.4270000Z

Lenny has sold his soul several times to try and keep going. This is his 7th rodeo and the bulls keep trampling his arst in the ground. Look for more pumping from the same posters, over and over again. GL Ty...

Play Episode

6min

Proactive - Interviews for investors

Race Oncology launches Phase I RC220 trial in Australia

Race Oncology CEO and MD Daniel Tillett talked with Proactive about the opening of patient enrollment at the first Australian clinical site for the RC220 Phase I solid tumour trial. Tillett confirmed that the trial is now underway, with additional sites expected to follow soon. The focus of this early-stage study is to determine a safe and effective combination dose of RC220 with the chemotherapy drug doxorubicin. According to Tillett, “our drug has the advantage… not only does it improve the anti-cancer treatment, but it protects the heart, at least in animals and cells to date.” He noted the choice of Southside Cancer Centre as the initial site, citing the faster startup process compared to public hospitals. Other sites, including Gosford and Wyong, have also received ethics approval and are expected to join the trial following regulatory clearance. Tillett discussed the use of a Bayesian trial design, which allows quicker progression and minimises patient exposure to suboptimal doses. While this approach can introduce uncertainty in timelines, it is expected to be more beneficial overall for patients and the company. Early preclinical data has shown that RC220 can reduce doxorubicin-related toxicity while enhancing cancer treatment outcomes, a combination Tillett described as unique among current therapies. Beyond the trial, Race Oncology is conducting separate preclinical studies to identify the most effective drug combinations using RC220. Tillett noted that more updates on this work are expected in the coming months. Watch the full video to hear more from Daniel Tillett and stay informed on Race Oncology’s developments. ➡️ For more interviews like this, visit Proactive’s YouTube channel. Don’t forget to like the video, subscribe to the channel, and hit the notification bell for future updates. #RaceOncology #RC220 #CancerResearch #ClinicalTrials #OncologyUpdates #Doxorubicin #CardioProtection #BayesianDesign #CancerTreatment #BiotechNews #ProactiveInve

Proactive - Interviews for investors

ATOME signs milestone EPC deal with Casale for Villeta project

ATOME PLC (AIM:ATOM) CEO Olivier Mussat talked with Proactive about a landmark milestone for the company’s Villeta green fertiliser project in Paraguay. The company has signed its first definitive engineering, procurement and construction (EPC) agreement with Swiss firm Casale S.A. Mussat explained that this agreement marks the world’s first large-scale green hydrogen fertiliser project to reach the EPC stage, underlining its global relevance. “It’s significant for us as a company because we’ve announced that we had been working on the front-end engineering and design for more than two years now,” Mussat said, noting the long-term collaboration with Casale. He highlighted Casale’s industry-leading expertise, describing the firm as the oldest ammonia licensor globally, with the ability to deliver complex, full-chain fertiliser projects. According to Mussat, the partnership serves as a strategic blueprint for Casale’s future growth. Looking ahead, ATOME aims to reach a final investment decision on the Villeta project by the end of the first half of the year. The company is working to finalise offtake agreements and complete financial documentation for both debt and equity funding. This includes a $115 million equity commitment from Hy24, with further syndication in progress. For more updates on green hydrogen and clean energy developments, visit Proactive’s YouTube channel. Like this video, subscribe, and turn on notifications to stay informed. #ATOMEPLC #GreenHydrogen #EPCContract #FertilizerProject #Casale #SustainableEnergy #CleanTech #HydrogenEconomy #ParaguayProjects #Yara #Hy24

Proactive - Interviews for investors

Solvonis Therapeutics engages PharmaVentures to support key AUD assets

Solvonis Therapeutics PLC (LSE:SVNS) CEO Anthony Tennyson talked with Proactive about the company's strategic move to commercialise two clinical-stage assets targeting alcohol use disorder (AUD). Tennyson explained that Solvonis has engaged PharmaVentures to support valuation and potential out-licensing for two lead programs—AWKN-001 and AWKN-002. PharmaVentures was chosen based on its three-decade track record in biopharma M&A advisory, with over 1,000 deals completed. Tennyson noted, “We’ve selected them for three reasons: their expertise, their experience, and their reach.” The two assets originated from Solvonis's planned acquisition of Awakn Life Sciences, a transaction expected to be completed in the second quarter. AWKN-001, now in Phase 3 trials, targets severe AUD in the UK and EU. PharmaVentures estimates the asset could yield around £60 million in upfront and milestone payments, plus significant double-digit royalties. AWKN-002, focused on moderate to severe AUD in the US, is in Phase 2B planning. This program could generate approximately £150 million, based on comparable transactions. Tennyson emphasised the unmet medical need, citing a 75% relapse rate within a year for current AUD treatments. “That represents a significant commercial opportunity for Solvonis,” he said. For more interviews like this, visit Proactive's YouTube channel. Give this video a like, subscribe, and enable notifications to stay updated. #SolvonisTherapeutics #AlcoholUseDisorder #BiotechNews #ClinicalTrials #AWKN001 #AWKN002 #AddictionTreatment #PharmaVentures #MentalHealthInnovation #BiopharmaDeals #InvestorUpdate #HealthcareStocks #Phase3Trial #Outlicensing #Q2Milestones

Proactive - Interviews for investors

Nostra Terra Oil and Gas CEO on Fouke field growth plans, 5,000 barrels a day target

Nostra Terra Oil and Gas Company PLC CEO Paul Welch talked with Proactive's Stephen Gunnion about the company’s strategy to scale up production and drive growth from its existing base of operations in East Texas and West Texas. Welch explained that Nostra Terra is currently focused on the Pine Mills field, a long-life, shallow onshore field with low operating costs and consistent profitability. “It's been an exciting field for the last 75 years and we expect it to be an exciting field for the program for the next 20 to 30 as well,” he said. Since taking over as CEO around nine months ago, Welch has led the company to profitability by cutting costs and increasing production. He highlighted two successful well workover programs that have effectively doubled production. A key highlight is the Fouke area, where new drilling, including the upcoming Fouke-3 well, could deliver significant volumes. Welch pointed out that these wells can initially produce around 120 barrels per day—compared to the average of 6 to 10 barrels from the Pine Mills wells. If enhanced recovery schemes are implemented, the output could potentially double. Welch reaffirmed the company’s ambitious growth target: “This is a company that's going to be making 5,000 barrels a day in the next 3 to 5 years.” The focus remains on building from a solid, profitable base, with production costs in the Fouke area as low as $3 to $4 per barrel, ensuring resilience across various oil price environments. Watch the full interview to hear more on the outlook for 2025, drilling plans, and the strategic path forward. For more interviews like this, visit Proactive’s YouTube channel. Don’t forget to like the video, subscribe to our channel, and enable notifications to stay updated on the latest content. #NostraTerra #OilAndGas #PaulWelch #TexasOil #PineMillsField #FoukeArea #EnergyStocks #OilProduction #InvestorUpdate #ProactiveInvestors

Followers	28
Posts	1939
Boards Moderated	0
Alias Born	02/27/2014

Volume:
Day Range:
Bid:
Ask:
Last Trade Time:
Total Trades:

Volume
Day Range:
Bid Price
Ask Price
Last Trade Time:

Boards:

Quotes:

Boards

News

Market Data

Markets

Discover

Discover

Boards:

Quotes:

Detailed Quote

Recent INKW News

More INKW News

Boards:

Quotes:

Boards

News

Market Data

Markets

Discover

Discover

Boards:

Quotes:

Recent INKW News

Go Ad-Free